Blauvelt, A., Warren, R., Reich, K. and al., et 2019. Durable Improvement in Patient Reported Outcomes across DLQI Subdomains Over 48 Weeks in Chronic Plaque Psoriasis Patients Treated with Certolizumab Pegol in Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2). SKIN The Journal of Cutaneous Medicine. 3, 2 (Mar. 2019), 175. DOI:https://doi.org/10.25251/skin.3.2.15.